Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
āļŦāļļāđāļāļŠāļēāļĒāļāļēāļĢāļāļīāļāļĒāļļāđāļĢāļāļāļļāđāļāļāļķāđāļāđāļĢāļ
āļŠāļĢāļļāļāļ āļēāļāļĢāļ§āļĄāļāļĨāļēāļ: āļāđāļēāļ§āļĨāļ·āļāļŠāļąāļāļāļīāļ āļēāļāđāļĨāļ°āļāļĨāļāļĢāļ°āļāļāļāļāļēāļĢāļāļĩāđāļāđāļēāļāļīāļāļŦāļ§āļąāļ
Trump āļāļĢāļ°āļāļēāļĻāļāđāļāļāļāļĨāļāļŦāļĒāļļāļāļĒāļīāļāļĢāļ°āļŦāļ§āđāļēāļāļāļīāļŠāļĢāļēāđāļāļĨāđāļĨāļ°āđāļĨāļāļēāļāļāļ
Netflix āļĢāđāļ§āļ 9% āļŦāļĨāļąāļāļĢāļēāļĒāļāļēāļāļāļĨāļāļĢāļ°āļāļāļāļāļēāļĢāđāļāļĢāļĄāļēāļŠ 1 ð
